Twenty participants from Australia, Belgium, Denmark, Finland, France, Germany, Italy, Israel, The Netherlands, Sweden, UK and the USA met in Naarden, The Netherlands from December 8th-10th, 2017. This group included clinicians, clinical trialists, basic scientists, industry and patient representatives. Patients were represented by the Muscular Dystrophy Association and Alexander’s Way (BAG3 associated myopathy). The goals were to discuss the role of protein chaperones in normal muscle function, muscle disease and future therapies.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...